Genmab — December 2014
-
En lille julegave! https://clinicaltrials.gov/ct2/show/NCT02195479?term=daratumumab&rank=9
-
mon ikke vi får at indtægtsføre milestone i år også så?
-
Gen er en FA aktie! Der er kun en vej og det er at købe EKSTRA hver gang den falder. De fleste stigninger Bekræfter potentialet og casen. Den oprindelige inv er sikret og jeg har de sidste tre år kun øget og det vel at mærke flere gange årligt. At tro vi er på toppen eller nær den vil fortryde s bitterligt. Dette er det omvendte af "faldende knive"
-
Dr Richardson: The anti-CD38 antibodies were the real stars of the show, after the very promising important data from both ASPIRE and STRATUS, and then, of course, ixazomib. But then to have the drumroll build to a crescendo with the arrival of the two antibodies was really something. (Om ASH 2014
og CD38)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind